Pilié Patrick G, Johnson Anna M, Hanson Kristen L, Dayno Megan E, Kapron Ashley L, Stoffel Elena M, Cooney Kathleen A
Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan.
Cancer. 2017 Oct 15;123(20):3925-3932. doi: 10.1002/cncr.30817. Epub 2017 Jun 28.
Prostate cancer has a significant heritable component, and rare deleterious germline variants in certain genes can increase the risk of the disease. The aim of the current study was to describe the prevalence of pathogenic germline variants in cancer-predisposing genes in men with prostate cancer and at least 1 additional primary cancer.
Using a multigene panel, the authors sequenced germline DNA from 102 men with prostate cancer and at least 1 additional primary cancer who also met ≥1 of the following criteria: 1) age ≤55 years at the time of diagnosis of the first malignancy; 2) rare tumor type or atypical presentation of a common tumor; and/or 3) ≥3 primary malignancies. Cancer family history and clinicopathologic data were independently reviewed by a clinical genetic counselor to determine whether the patient met established criteria for testing for a hereditary cancer syndrome.
Sequencing identified approximately 3500 variants. Nine protein-truncating deleterious mutations were found across 6 genes, including BRCA2, ataxia telangiectasia mutated (ATM), mutL homolog 1 (MLH1), BRCA1 interacting protein C-terminal helicase 1 (BRIP1), partner and localizer of BRCA2 (PALB2), and fibroblast growth factor receptor 3 (FGFR3). Likely pathogenic missense variants were identified in checkpoint kinase 2 (CHEK2) and homeobox protein Hox-B13 (HOXB13). In total, 11 of 102 patients (10.8%) were found to have pathogenic or likely pathogenic mutations in cancer-predisposing genes. The majority of these men (64%) did not meet current clinical criteria for germline testing.
Men with prostate cancer and at least 1 additional primary cancer are enriched for harboring a germline deleterious mutation in a cancer-predisposing gene that may impact cancer prognosis and treatment, but the majority do not meet current criteria for clinical genetic testing. Cancer 2017;123:3925-32. © 2017 American Cancer Society.
前列腺癌具有显著的遗传成分,某些基因中罕见的有害种系变异可增加患该疾病的风险。本研究的目的是描述前列腺癌男性且至少患有一种其他原发性癌症患者中,癌症易感基因中致病种系变异的患病率。
作者使用多基因检测板,对102名前列腺癌男性且至少患有一种其他原发性癌症的患者的种系DNA进行测序,这些患者还符合以下至少一项标准:1)首次恶性肿瘤诊断时年龄≤55岁;2)罕见肿瘤类型或常见肿瘤的非典型表现;和/或3)≥3种原发性恶性肿瘤。癌症家族史和临床病理数据由临床遗传咨询师独立审查,以确定患者是否符合遗传性癌症综合征检测的既定标准。
测序鉴定出约3500个变异。在6个基因中发现了9个蛋白质截短的有害突变,包括BRCA2、共济失调毛细血管扩张突变基因(ATM)、错配修复蛋白1(MLH1)、BRCA1相互作用蛋白C末端解旋酶1(BRIP1)、BRCA2的伴侣和定位蛋白(PALB2)和成纤维细胞生长因子受体3(FGFR3)。在细胞周期检查点激酶2(CHEK2)和同源盒蛋白Hox-B13(HOXB13)中鉴定出可能致病的错义变异。总共,102名患者中有11名(10.8%)被发现在癌症易感基因中存在致病或可能致病的突变。这些男性中的大多数(64%)不符合目前种系检测的临床标准。
患有前列腺癌且至少有一种其他原发性癌症的男性,其癌症易感基因中携带种系有害突变的情况更为常见,这可能会影响癌症的预后和治疗,但大多数不符合目前临床基因检测的标准。《癌症》2017年;123:3925 - 32。©2017美国癌症协会。